Merck's Keytruda Strength Continues Ahead of U.S. Patent Expiration
Dow Jones10-29 21:30
0930 ET - Merck's blockbuster cancer treatment Keytruda generated nearly half of the company's total worldwide sales in the third quarter, with sales of the drug up 6% to $8.6 billion. Merck attributed the drug's growth to uptake in earlier-stage indications, as well as a new form of the drug called Qlex, which is administered by injection. Keytruda is set to lose its main U.S. patent protection in 2028, and Merck has acquired a string of targeted assets--including its 2021 acquisition of Acceleron, which gave it the fast-growing pulmonary-hypertension drug Winrevair--to help offset some of that upcoming pressure.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments